Monitoring of lipodystrophic and metabolic abnormalities in HIV-1 infected children on antiretroviral therapy

Hormones

Volumn 10, Issue 2, 2011, Pages 149-155

  Spoulou, Vana ^a   Kanaka Gantenbein, Christina ^a   Bathrellou, Irini ^b   Mora, Stefano ^c   Mostrou, Glyceria ^a   Sidossis, Lambros ^b   Chrousos, George ^a   Theodoridou, Maria ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b HAROKOPIO UNIVERSITY   (Greece)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Antiretroviral therapy; Children; DXA; Dyslipidemia; HIV; Lipodystrophy

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; GLUCOSE; PROTEINASE INHIBITOR; TRIACYLGLYCEROL;

AGE; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; CHILD; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIPID BLOOD LEVEL; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PHENOTYPE; PRESCHOOL CHILD; SEX DIFFERENCE; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79959191348     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1305     Document Type: Article

References (22)

1. Grinspoon S, Carr A, 2005 Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352: 48-62.
2. Leow MK, Addy CL, Mantzoros CS, 2003 Clinical review 159: Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab 88: 1961-1976.
3. Jaquet D, Levine M, Ortega-Rodriguez E, et al, 2000 Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 14: 2123-2128.
4. Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW, 2002 Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 21: 405-410.
5. Taylor P, Worrell C, Steinberg SM, et al, 2004 Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. Pediatrics 114: e235-242.
6. Ellis KJ, Shypailo RJ, Pratt JA, Pond WG, 1994 Accuracy of dual-energy x-ray absorptiometry for bodycomposition measurements in children. Am J Clin Nutr 60: 660-665.
7. Vigano A, Mora S, Testolin C, et al, 2003 Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr 32: 482-489.
8. Brambilla P, Bricalli D, Sala N, et al, 2001 Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS 15: 2415-2422.
9. Aurpibul L, Puthanakit T, Lee B, Mangklabruks A, Sirisanthana T, Sirisanthana V, 2007 Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Antivir Ther 12: 1247-1254.
10. Krause JC, Toye MP, Fisher DJ, Stechenberg BW, Reiter EO, Allen HF, 2009 Metabolic abnormalities in human immunodeficiency virus-infected children: two-year follow-up. J Pediatr Endocrinol Metab 22: 345-351.
11. Parakh A, Dubey AP, Kumar A, Maheshwari A, 2009 Lipodystrophy and metabolic complications of highly active antiretroviral therapy. Indian J Pediatr 76: 1017-1021.
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, 1985 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
13. Fernandez J, Redden D, Pietrobelli A, Allison D, 2004 Waist circumference percentiles innationally representative sampes of African-American,European-American and Mexican-American children and adolescents. J Pediatr 145: 439-444.
14. Schulpis K, Karikas GA, 1998 Serum cholesterol and triglyceride distribution in 7767 school-aged Greek children. Pediatrics 101: 861-864.
15. European Pediatric Lipodystrophy Group, 2004 Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 18: 1443-1451.
16. Sanchez Torres AM, Munoz Muniz R, Madero R, Borque C, Garcia-Miguel MJ, De Jose Gomez MI, 2005 Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr 164: 271-276.
17. Haubrich RH, Riddler SA, DiRienzo AG, et al, 2009 Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 23: 1109-1118.
18. Beregszaszi M, Dollfus C, Levine M, et al, 2005 Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 40: 161-168.
19. Kino T, Chrousos GP, 2003 AIDS-related insulin resistance and lipodystrophy syndrome. Curr Drug Targets Immune Endocr Metabol Disord 3: 111-117.
20. Bitnun A, Sochett E, Babyn P, et al, 2003 Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naïve HIV-infected children. AIDS 17: 1319-1327.
21. Bitnun A, Sochett E, Dick PT, et al, 2005 Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naive human immunodeficiency virus-infected children. J Clin Endocrinol Metab 90: 168-174.
22. Plebani A, Esposito S, Pinzani R, et al, 2004 Effect of highly active antiretroviral therapy on cardiovascular involvement in children with human immunodeficiency virus infection. Pediatr Infect Dis J 23: 559-563.